Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms

"Induction chemotherapy for patients with AML eligible for intensive chemotherapy:~* Cytarabine 200 mg/m2 IV continuous infusion days 1-7~* Daunorubicin 90 mg/m2 intravenous piggyback days 1-3"

"Consolidation chemotherapy for patients eligible for intensive chemotherapy with low-risk AML or patients with intermediate-/high-risk AML who do not have matched donors:~-Cytarabine 1.5 g/m2 IV in 3 hours days 1, 3 and 5 for 3 cycles"

"Autologous Stem Cell Transplantation for consolidation of patients eligible for intensive chemotherapy with low-risk AML or patients with intermediate-/high-risk AML who do not have matched donors:~* Busulfan 1 mg/Kg PO q6h or 130 mg/m2 IV once daily days -7 to -4~* Cyclophosphamide 60 mg/Kg IV once daily days -3 and -2"

"Allogeneic Stem Cell Transplantation for consolidation of patients eligible for intensive chemotherapy with intermediate-/high-risk AML~Conditioning regimen:~* Busulfan 1 mg/Kg PO q6h or 130 mg/m2 IV once daily days -7 to -4~* Cyclophosphamide 60 mg/Kg IV once daily days -3 and -2 or Fludarabine 40 mg/m2 IV once daily days -7 to -4"

"Chemotherapy for patients with AML who are not fit for intensive chemotherapy:~* Cytarabine 60 mg/m2 subcutaneous (SQ) bid days 1-5 (until CR or maximum 4 cycles)~* Cytarabine 40 mg/m2 SQ bid days 1-5 (after CR, until a maximum of 3 years of therapy or relapse, whichever comes first)"

"Chemotherapy for patients with AML who are not fit for intensive chemotherapy:~* Decitabine 20 mg/m2 IV once daily days 1-10 (until CR or maximum 4 cycles)~* Decitabine 20 mg/m2 IV once daily days 1-5 (after CR, until a maximum of 3 years of therapy or relapse, whichever comes first)"